Multiple Genotypen bei Ashkenazim mit Faktor-XI-Mangel

Zusammenfassung

Die Struktur des Faktor-XI-Gens wurde bei sechs nicht verwandten Ashkenazim mit Faktor-XI-Mangel analysiert. Es wurden keine groben Veränderungen dieser Gene durch Southern-Blot-Analyse der genomischen DNA gefunden. Die Klonierung der Faktor-XI-Gene, die Polymerase-Chain-Reaction(PCR)-Analyse und die Sequenzierung der Exone und der Exon/Intron-Verbindungen machte es möglich, eine Mutation der Spleiß Verbindung, eine Nonsens-Mutation und eine SauSAI-Mutation zu identifizieren. Diese drei Arten von Allelen zusammen erklären alle genetischen Defekte bei diesen sechs Personen. Das Vorkommen multipler Allelmutationen läßt die Hypothese des selektiven Vorteils gegenüber der genetischen Verschiebungshypothese als Erklärung des Überlebens des abnormen Faktor-XI-Gens wahrscheinlicher erscheinen.

• LITERATUR

• 1 Arpaia E, Dumbrill-Ross A, Maler T, Neote K, Tropak M, Troxel C, Stirling J L, Pitts J S, Bapat B, Lamhonwah A M, Mahuran D J, Schuster S M, Clarke J T R, Lowden J A, Gravel R A. Identification of an altered splice site in Ashkenazi Tay-Sachs disease. Nature 1988; 333: 85-6.
• 2 Asakai R, Davie E W, Chung D W. Organization of the gene for human factor XI. Biochemistry 1987; 26: 7221-8.
• 3 Bolton-Maggs P H B, Wan-Yin B Y, McCraw A H, Slack J, Kernoff P B A. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988; 69: 521-8.
• 4 Bouma B N, Griffin J H. Human blood coagulation factor XI: purification properties and mechanism of activation by activated factor XII. J Biol Chem 1977; 252: 6432-7.
• 5 Breathnach R, Chambon P. Organization and expression of eukaryotic split genes coding for proteins. Ann Rev Biochem 1981; 50: 349-83.
• 6 Brenner S. The molecular evolution of genes and protein: a tale of two serines. Nature 1988; 334: 528-30.
• 7 Chung D W, Fujikawa K, McMullen B A, Davie E W. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 1986; 25: 2410-7.
• 8 Cool D E, MacGillivray R T A. Characterization of the human blood coagulation factor XII gene. J Biol Chem 1987; 262: 13662-73.
• 9 Diamond J M, Rotter J I. Observing the founder effect in human evolution. Nature 1987; 329: 105-6.
• 10 Dilella A G, Marvit J, Lidsky A S, Gutler F, Woo S L. Tight linkage between a splicing mutation and specific DNA haplotype in phenylketonuria. Nature 1986; 322: 799-803.
• 11 Dzik W H, Arkin C F, Jenkins R L. Transfer of congenital factor XI deficiency from a donor to a recipient by liver transplantation. N Engl J Med 1987; 316: 1217-8.
• 12 Fujikawa K, Saito H. Contact activation. In: Scriver C R, Beaudet A L, Sly W S, Valle D. (Eds). Metabolic Basis of Inherited Disease. 6th. Ed. New York: McGraw-Hill; 1988
• 13 Fujikawa K, Chung D W, Hendrickson L E, Davie E W. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 1986; 25: 2417-24.
• 14 Fujikawa K, Legas M E, Kato H, Davie E W. The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XI a (activated plasma thromboplastin antecedent). Biochemistry 1974; 13: 4508-16.
• 15 Goldfarb P S. Evolution of modern proteins. Nature 1988; 336: 429.
• 16 Goodman R M. Genetic Disorders Among the Jewish People. Baltimore, London: Johns Hopkins University Press; 1979
• 17 Griffin J H, Cochrane C G. Mechanisms for the involvement of high-molecular-weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci USA 1976; 73: 2554-8.
• 18 Humphries R K, Ley T J, Anagnou N P, Baur A W, Nienhuis A W. Beta-thalassemia gene for premature termination codon causes beta-mRNA deficiency without changing cytoplasmic beta-mRNA stability. Blood 1984; 64: 23-32.
• 19 Irwin D M. Evolution of an active-site codon in serine proteases. Nature 1988; 336: 429-30.
• 20 Kurachi K, Fujikawa K, Davie E W. Mechanism of activation of bovine factor XI by factor XII and factor XII a. Biochemistry 1980; 19: 1330-8.
• 21 Kurachi K, Davie E W. Activation of human factor XI (plasma thromboplastin antecedent) by factor XII a (activated Hageman factor). Biochemistry 1977; 16: 5831-9.
• 22 Mannhalter C, Hellstern P, Deutsch E. Identification of a defective factor XI crossreacting material in a factor XI-deficient patient. Blood 1987; 70: 31-7.
• 23 Mount S M. A catalogue of splice junction sequences. Nucleic Acids Res 1982; 10: 459-72.
• 24 Movat H Z, Ozge-Anwar A H. The contact phase of blood coagulation: clotting factors XI and XII, their isolation and interaction. J Lab Clin Med 1974; 84: 861-78.
• 25 Musclow C E, Goldenberg H, Bernstein P, Abbott D. Factor XI deficiency presenting as hemarthrosis during pregnancy. Am J Obstet Gynecol 1987; 157: 178-9.
• 26 Myerowitz R. Splice junction mutation in some Ashkenazi Jews with Tay-Sachs disease : evidence against a single defect within this ethinic group. Proc Natl Acad Sci USA 1988; 85: 3955-9.
• 27 Ragni M V, Sinha D, Seaman F, Lewis J H, Spero J A, Walsh P N. Comparison of bleeding tendency, factor XI coagulant activity, and Factor XI antigen in twenty-five Factor XI deficiènt kindreds. Blood 1985; 65: 719-24.
• 28 Rapaport S I, Proctor R R, Patch M J, Yeltra M. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency. Blood 1961; 18: 149-65.
• 29 Ratnoff O D, Davie E W, Mallett D L. Studies on the action of Hagemann factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J Clin Invest 1961; 40: 803-19.
• 30 Rees D J, Rizzia C R, Brownlee G G. Hemophilia B caused by a point mutation in a donor splice junction of human factor IX gene. Nature 1985; 31: 643-5.
• 31 Rosenthal R L, Dreskin O H, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 1953; 82: 171-4.
• 32 Rotter J I, Diamond J M. What maintains the frequencies of human genetic diseases?. Nature 1987; 329: 289-90.
• 33 Saiki R K, Scharf S, Faloona F, Mullis K B, Horn G T, Erlich H A, Arnheim N. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230: 1350-4.
• 34 Saito H, Goldsmith Jr G H. Plasma thromboplastin antecedent (PTA, factor XI): a specific and sensitive radioimmunoassay. Blood 1977; 50: 377-85.
• 35 Saito H, Ratnoff O D, Bouma B N, Seligsohn U. Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deficiency: a study of 125 patients of several ethnic backgrounds. J Lab Clin Med 1985; 106: 718-22.
• 36 Scharf S J, Horn G T, Erlich H A. Direct cloning and sequence analysis of enzymatically amplified genomic sequences. Science 1986; 233: 1076-8.
• 37 Schmaier A H, Silverberg M, Kaplan A P, Colman R W. Contact activation and its abnormalities. In: Colman R W, Hirsh J, Marder V J, Salzman E W. (eds). Hemostasis and Thrombosis. 2nd. Ed. (Lippincott, Philadelphia). Philadelphia: Lippincott; 1987
• 38 Seligsohn U. Factor XI (PTA) deficiency. In: Goodman R M, Motulsky A G. (Eds). Genetic Diseases Among Ashkenazi Jews. New York: Raven Press; 1979: 141-7.
• 39 Takeshita K, Forget B G, Scarpa A, Benz Jr E J. Intranuclear defect in beta-globin mRNA accumulation due to a premature translation termination codon. Blood 1984; 64: 13-22.
• 40 Thompson R E, Mandle Jr R, Kaplan A P. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60: 1376-80.
• 41 Treisman R, Proudfoot N J, Shander M, Maniatis T. A single-base change at a splice site in a beta 0-thalassemic gene causes abnormal RNA splicing. Cell 1982; 29: 903-11.
• 42 Tsuji S, Martin B M, Barranger J A, Stubblefield B K, LaMarcia M E, Ginns E I. Genetic heterogeneity in type I Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. Proc Natl Acad Sci USA 1988; 85: 2349-52.
• 43 Walsh P N. Platelet-mediated coagulant protein interactions in hemostasis. Semin Hematol 1985; 22: 178-86.